Below are the most recent publications written about "Cost Savings" by people in Profiles.
-
Banh C, Valsvik K, Arredondo A, Notbohm K, Elquza E, Babiker H, Kraft A, Boiles AR, Persky D, Ortega A, McBride A. Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30(3):2755-2766.
-
Taber DJ, Fleming JN, Su Z, Mauldin P, McGillicuddy JW, Posadas A, Gebregziabher M. Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients. Am J Transplant. 2021 10; 21(10):3428-3435.
-
Bisognano J, Schneider JE, Davies S, Ohsfeldt RL, Galle E, Stojanovic I, Deering TF, Lindenfeld J, Zile MR. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
-
Anderson BR, Gotlieb EG, Hill K, McHugh KE, Scheurer MA, Mery CM, Pelletier GJ, Kaltman JR, White OJ, Trachtenberg FL, Hollenbeck-Pringle D, McCrindle BW, Sylvester DM, Eckhauser AW, Pasquali SK, Anderson JB, Schamberger MS, Shashidharan S, Jacobs JP, Jacobs ML, Boskovski M, Newburger JW, Nathan M. Registry-based trials: a potential model for cost savings? Cardiol Young. 2020 Jun; 30(6):807-817.
-
Brothers TE, Todoran TM. Permanent inferior vena cava filters offer greater expected patient utility at lower predicted cost. J Vasc Surg Venous Lymphat Disord. 2020 07; 8(4):583-592.e5.
-
Rudzinski PN, Kruk M, Kepka C, Schoepf UJ, Otani K, Leonard TJ, Debski M, Dzielinska Z, Pregowski J, Witkowski A, Ruzyllo W, Demkow M. Assessing the value of coronary artery computed tomography as the first-line anatomical test for stable patients with indications for invasive angiography due to suspected coronary artery disease. Initial cost analysis in the CAT-CAD randomized trial. J Cardiovasc Comput Tomogr. 2020 Jan - Feb; 14(1):75-79.
-
Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Picone MF, Wisniewski CS, Hayes GL. Use of economic predictions to make formulary decisions. Am J Health Syst Pharm. 2019 Feb 08; 76(Supplement_1):S15-S20.
-
Vest JR, Harris LE, Haut DP, Halverson PK, Menachemi N. Indianapolis Provider's Use Of Wraparound Services Associated With Reduced Hospitalizations And Emergency Department Visits. Health Aff (Millwood). 2018 10; 37(10):1555-1561.
-
Murphy SME, Hough DE, Sylvia ML, Dunbar LJ, Frick KD. Key Design Considerations When Calculating Cost Savings for Population Health Management Programs in an Observational Setting. Health Serv Res. 2018 08; 53 Suppl 1:3107-3124.